EZH2 accompanies prostate cancer progression.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.Cancer research · 2026
   Article
2. UHRF1 regulates AR ubiquitination to promote the loss of AR signaling and enzalutamide resistance in progression of prostate cancer.Cell death & disease · 2026
   Article
3. The Research Progress of Tumor-Associated Macrophages in Prostate Cancer.Journal of immunology research · 2026
   Review
4. Bibliometric Insights into Aging and Immune Function in Prostate Cancer: Focus on Chronic Inflammation.Journal of inflammation research · 2026
   Review
5. Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer.Scientific reports · 2025
   Article
6. A PHF19-YTHDC1 condensate switches EZH2-mediated gene suppression to activation for prostate cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2025
   Article
7. EZH2 Dysregulation and Its Oncogenic Role in Human Cancers.Cancers · 2025
   Review
8. Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025
   Review
9. A Promising Breakthrough for Triple-Negative Breast Cancer by Targeting the AKT and EZH2.MedComm · 2025
   Article
10. A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma.Journal of hematology & oncology · 2025
    Article
11. SETD2 and EZH2: Two epigenetic drivers of prostate cancer.Journal of Cancer · 2025
    Review
12. Epigenetic and Immune Profile Characteristics in Sinonasal Undifferentiated Carcinoma.Cancer medicine · 2024
    Article
13. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.Oncogene · 2024
    Article
14. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.Nature communications · 2024
    Article
15. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.Frontiers in oncology · 2024
    Review
16. Epigenetic markers and therapeutic targets for metastasis.Cancer metastasis reviews · 2023
    Review
17. Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.PLoS biology · 2023
    Article
18. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia.Frontiers in oncology · 2023
    Article
19. PRADclass: Hybrid Gleason Grade-Informed Computational Strategy Identifies Consensus Biomarker Features Predictive of Aggressive Prostate Adenocarcinoma.Technology in cancer research & treatment
    Article

Corrections and comments

• Comment on
  An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as